180 related articles for article (PubMed ID: 38319706)
1. Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma.
Wu B; Zhang X; Feng N; Guo Z; Gao L; Wan Z; Zhang W
Aging (Albany NY); 2024 Feb; 16(3):2273-2298. PubMed ID: 38319706
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel anoikis-related gene signature to predict prognosis and tumor microenvironment in lung adenocarcinoma.
Diao X; Guo C; Li S
Thorac Cancer; 2023 Jan; 14(3):320-330. PubMed ID: 36507553
[TBL] [Abstract][Full Text] [Related]
3. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
5. Development of the prognostic value in lung adenocarcinoma based on anoikis-related genes and initial experimental validation.
Guo W; Zhao G; Liu S; Deng T; Zhang G; Zhang B
J Gene Med; 2023 Sep; 25(9):e3534. PubMed ID: 37259225
[TBL] [Abstract][Full Text] [Related]
6. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
7. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
[TBL] [Abstract][Full Text] [Related]
8. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
[TBL] [Abstract][Full Text] [Related]
9. Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma.
Zhuang J; Chen Z; Chen Z; Chen J; Liu M; Xu X; Liu Y; Yang S; Hu Z; He F
Respir Res; 2022 May; 23(1):123. PubMed ID: 35562727
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value and immune landscapes of immunogenic cell death-associated lncRNAs in lung adenocarcinoma.
Shu K; Cai C; Chen W; Ding J; Guo Z; Wei Y; Zhang W
Sci Rep; 2023 Nov; 13(1):19151. PubMed ID: 37932413
[TBL] [Abstract][Full Text] [Related]
11. An anoikis-related lncRNA signature is a useful tool for predicting the prognosis of patients with lung adenocarcinoma.
Jiang X; Gao YL; Li JY; Tong YY; Meng ZY; Yang SG; Zhu CT
Heliyon; 2023 Nov; 9(11):e22200. PubMed ID: 38053861
[TBL] [Abstract][Full Text] [Related]
12. A novel signature based on autophagy-related lncRNA for prognostic prediction and candidate drugs for lung adenocarcinoma.
Gong Z; Li Q; Li J; Xie J; Wang W
Transl Cancer Res; 2022 Jan; 11(1):14-28. PubMed ID: 35261881
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
Front Genet; 2022; 13():838624. PubMed ID: 35928454
[TBL] [Abstract][Full Text] [Related]
15. A novel anoikis-related gene signature to predict the prognosis, immune infiltration, and therapeutic outcome of lung adenocarcinoma.
Wang Y; Xie C; Su Y
J Thorac Dis; 2023 Mar; 15(3):1335-1352. PubMed ID: 37065587
[TBL] [Abstract][Full Text] [Related]
16. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
[TBL] [Abstract][Full Text] [Related]
17. A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in lung adenocarcinoma.
Liu Y; Hu S; Teng M; Qing Y; Dong X; Chen L; Ai K
J Gene Med; 2024 Feb; 26(1):e3610. PubMed ID: 37985130
[TBL] [Abstract][Full Text] [Related]
18. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria-related lncRNAs: predicting prognosis, tumor microenvironment and treatment response in lung adenocarcinoma.
Zhou Q; Xiong J; Gao Y; Yi R; Xu Y; Chen Q; Wang L; Chen Y
Funct Integr Genomics; 2023 Oct; 23(4):323. PubMed ID: 37864709
[TBL] [Abstract][Full Text] [Related]
20. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]